Symbols

BTMD

biote·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

MACD Golden Cross

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BTMD

Biote Corp.

A company that develops pharmaceuticals to treat hormonal imbalances in women and men

Industry

Healthcare Providers and Services

Established Date

07/06/2020

Listing Date

08/29/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

223

Fiscal Year Ends

12-31

Website

www.biote.com

Security Type

Common stock

Office address

1875 W. Walnut Hill Ln, #100, Irving, TX 75038

Business

Introduction

Biote Corp. was incorporated in Delaware on July 6, 2020. The company operates a high-growth practice building business within the hormone optimization space. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the following components specifically developed for practitioners in the field of hormone optimization: Biote Method education, training and certification, practice management software, inventory management software, and information on available hormone replacement therapy (" HRT ") products, as well as digital and point-of-care marketing support. The company also sells a complementary line of Biote-branded dietary supplements.

Company Financials

EPS

BTMD has released its 2025 Q4 earnings. EPS was reported at 0.06, versus the expected 0.09, missing expectations. The chart below visualizes how BTMD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BTMD has released its 2025 Q4 earnings report, with revenue of 46.41M, reflecting a YoY change of -6.87%, and net profit of 2.62M, showing a YoY change of -24.86%. The Sankey diagram below clearly presents BTMD's revenue sources and cost distribution.